puc-header

In Ovarian Cancer, the Concentration of Anti-Müllerian Hormone Dictates the Choice between Pro-Survival and Pro-Apoptotic Pathways Through Differential ALK2/ALK3 Usage

43 Pages Posted: 12 Dec 2019 Publication Status: Review Complete

See all articles by Maëva Chauvin

Maëva Chauvin

University of Montpellier - Institute for Cancer Research in Montpellier

Véronique Garambois

University of Montpellier - Institute for Cancer Research in Montpellier

Pierre-Emmanuel Colombo

University of Montpellier - Institute for Cancer Research in Montpellier

Myriam Chentouf

University of Montpellier - Institute for Cancer Research in Montpellier

Laurent Gros

University of Montpellier - Institute for Cancer Research in Montpellier

David-Paul De Brauwere

UNIMES - Université de Nîmes - Département de Biochimie et Biologie Moléculaire

Bruno Robert

University of Montpellier - Institute for Cancer Research in Montpellier

Alain Mangé

University of Montpellier - Institute for Cancer Research in Montpellier

Marta Jalier

Cancer Institute of Montpellier (ICM) - Institut régional du Cancer de Montpellier

Karen Dumas

SurgiMAb

Pierre Martineau

University of Montpellier - Institute for Cancer Research in Montpellier

Isabelle Navarro-Teulon

University of Montpellier - Institute for Cancer Research in Montpellier

Thierry Chardès

University of Montpellier - Institute for Cancer Research in Montpellier

André Pèlegrin

University of Montpellier - Institute for Cancer Research in Montpellier

More...

Abstract

In ovarian carcinoma, anti-Müllerian hormone (AMH) type II receptor (AMHRII) and the AMH/AMHRII signaling pathway are potential therapeutic targets. Conversely, the role of the three AMH type I receptors (AMHRI; ALK2, ALK3 and ALK6) needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients’ tumor ascites, we found that ALK2 and ALK3 are the two main AMHRIs involved in AMH signaling at low and high AMH concentrations, respectively. As expected, high AMH concentrations were associated with apoptosis and decreased clonogenic survival through preferential ALK3 usage. Conversely low AMH concentrations improved cancer cell viability and survival via the ALK2 receptor. Moreover, the AMH siRNA and the anti-AMH antibody B10 inhibited AMH pro-survival effect in vitro and in vivo. These results open the way to an innovative therapeutic approach to suppress AMH proliferative effect, instead of administering high AMH doses to induce cancer cell apoptosis.

Suggested Citation

Chauvin, Maëva and Garambois, Véronique and Colombo, Pierre-Emmanuel and Chentouf, Myriam and Gros, Laurent and De Brauwere, David-Paul and Robert, Bruno and Mangé, Alain and Jalier, Marta and Dumas, Karen and Martineau, Pierre and Navarro-Teulon, Isabelle and Chardès, Thierry and Pèlegrin, André, In Ovarian Cancer, the Concentration of Anti-Müllerian Hormone Dictates the Choice between Pro-Survival and Pro-Apoptotic Pathways Through Differential ALK2/ALK3 Usage (November 11, 2019). Available at SSRN: https://ssrn.com/abstract=3501841 or http://dx.doi.org/10.2139/ssrn.3501841
This version of the paper has not been formally peer reviewed.

Maëva Chauvin

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Véronique Garambois

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Pierre-Emmanuel Colombo

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Myriam Chentouf

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Laurent Gros

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

David-Paul De Brauwere

UNIMES - Université de Nîmes - Département de Biochimie et Biologie Moléculaire ( email )

France

Bruno Robert

University of Montpellier - Institute for Cancer Research in Montpellier

163 rue Auguste Broussonnet
France

Alain Mangé

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Marta Jalier

Cancer Institute of Montpellier (ICM) - Institut régional du Cancer de Montpellier ( email )

France

Karen Dumas

SurgiMAb ( email )

France

Pierre Martineau

University of Montpellier - Institute for Cancer Research in Montpellier

163 rue Auguste Broussonnet
France

Isabelle Navarro-Teulon

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Thierry Chardès

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

André Pèlegrin (Contact Author)

University of Montpellier - Institute for Cancer Research in Montpellier ( email )

163 rue Auguste Broussonnet
France

Click here to go to Cell.com

Paper statistics

Downloads
42
Abstract Views
399
PlumX Metrics